Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis

被引:35
作者
Toyooka, Shinichi [1 ]
Kiura, Katsuyuki [2 ]
Takemoto, Mitsuhiro [3 ]
Oto, Takahiro
Takigawa, Nagio [2 ]
Fujiwara, Toshiyoshi [4 ]
Miyoshi, Shinichiro
Date, Hiroshi [5 ]
机构
[1] Okayama Univ Hosp, Dept Thorac Surg, Kita Ku, Okayama 7008558, Japan
[2] Okayama Univ Hosp, Dept Resp Med, Okayama 7008558, Japan
[3] Himeji Hosp, Japanese Red Cross Soc, Dept Radiol, Hyogo, Japan
[4] Okayama Univ Hosp, Dept Surg Gastroenterol, Okayama 7008558, Japan
[5] Kyoto Univ, Grad Sch Med, Dept Thorac Surg, Kyoto, Japan
关键词
Non-small-cell lung cancer; Induction chemoradiotherapy; N2; CONCURRENT THORACIC RADIOTHERAPY; RANDOMIZED CONTROLLED-TRIAL; COOPERATIVE-ONCOLOGY-GROUP; CHEMOTHERAPY; THERAPY; RADIATION; RESECTION; SURVIVAL;
D O I
10.1093/icvts/ivs028
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purpose of this study was to show the long-term outcome of induction chemoradiotherapy, using docetaxel and cisplatin with concurrent radiotherapy followed by surgery for non-small-cell lung cancer (NSCLC) with mediastinal nodal metastasis. Between January 2000 and July 2006, 22 consecutive NSCLC patients with pathologically proven mediastinal nodal metastasis were treated with tri-modality therapy. The regimen consisted of docetaxel and cisplatin plus concurrent radiation at a dose of 40-46 Gy. The induction therapy was followed by surgery 4-6 weeks later. The pulmonary resections were composed of a lobectomy in 19 patients, including 3 with a sleeve lobectomy, a bilobectomy in 2 patients and a left pneumonectomy in 1 patient. With a median follow-up duration of 8.7 years, the 3-year and 7-year overall survival (OS) rates for the entire population were 72.7 and 63.6%, respectively. Our results suggest that tri-modality therapy is promising for NSCLC patients with mediastinal nodal metastasis.
引用
收藏
页码:565 / 569
页数:5
相关论文
共 14 条
  • [1] Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
    Albain, Kathy S.
    Swann, R. Suzanne
    Rusch, Valerie W.
    Turrisi, Andrew T., III
    Shepherd, Frances A.
    Smith, Colum
    Chen, Yuhchyau
    Livingston, Robert B.
    Feins, Richard H.
    Gandara, David R.
    Fry, Willard A.
    Darling, Gail
    Johnson, David H.
    Green, Mark R.
    Miller, Robert C.
    Ley, Joanne
    Sause, Willliam T.
    Cox, James D.
    [J]. LANCET, 2009, 374 (9687) : 379 - 386
  • [2] CONCURRENT CISPLATIN/ETOPOSIDE PLUS CHEST RADIOTHERAPY FOLLOWED BY SURGERY FOR STAGES IIIA(N2) AND IIIB NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF SOUTHWEST-ONCOLOGY-GROUP PHASE-II STUDY-8805
    ALBAIN, KS
    RUSCH, VW
    CROWLEY, JJ
    RICE, TW
    TURRISI, AT
    WEICK, JK
    LONCHYNA, VA
    PRESANT, CA
    MCKENNA, RJ
    GANDARA, DR
    FOSMIRE, H
    TAYLOR, SA
    STELZER, KJ
    BEASLEY, KR
    LIVINGSTON, RB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) : 1880 - 1892
  • [3] Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an eastern cooperative oncology group trial
    Bonomi, P
    Kim, KM
    Fairclough, D
    Cella, D
    Kugler, J
    Rowinsky, E
    Jiroutek, M
    Johnson, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) : 623 - 631
  • [4] The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours
    Goldstraw, Peter
    Crowley, John
    Chansky, Kari
    Giroux, Dorothy J.
    Groome, Patti A.
    Rami-Porta, Ramon
    Postmus, Pieter E.
    Rusch, Valerie
    Sobin, Leslie
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : 706 - 714
  • [5] Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935
    Jaklitsch, Michael T.
    Herndon, James E., II
    Decamp, Malcolm M., Jr.
    Richards, William G.
    Kumar, Parvesh
    Krasna, Mark J.
    Green, Mark R.
    Sugarbaker, David J.
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2006, 94 (07) : 599 - 606
  • [6] Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer
    Katayama, H
    Ueoka, H
    Kiura, K
    Tabata, M
    Kozuki, T
    Tanimoto, M
    Fujiwara, T
    Tanaka, N
    Date, H
    Aoe, M
    Shimizu, N
    Takemoto, M
    Hiraki, Y
    [J]. BRITISH JOURNAL OF CANCER, 2004, 90 (05) : 979 - 984
  • [7] Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer
    Kiura, K
    Ueoka, H
    Segawa, Y
    Tabata, M
    Kamei, H
    Takigawa, N
    Hiraki, S
    Watanabe, Y
    Bessho, A
    Eguchi, K
    Okimoto, N
    Harita, S
    Takemoto, M
    Hiraki, Y
    Harada, M
    Tanimoto, M
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (05) : 795 - 802
  • [8] TOXICITY AND RESPONSE CRITERIA OF THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP
    OKEN, MM
    CREECH, RH
    TORMEY, DC
    HORTON, J
    DAVIS, TE
    MCFADDEN, ET
    CARBONE, PP
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1982, 5 (06): : 649 - 655
  • [9] Phase III Trial Comparing Docetaxel and Cisplatin Combination Chemotherapy With Mitomycin, Vindesine, and Cisplatin Combination Chemotherapy With Concurrent Thoracic Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: OLCSG 0007
    Segawa, Yoshihiko
    Kiura, Katsuyuki
    Takigawa, Nagio
    Kamei, Haruhito
    Harita, Shingo
    Hiraki, Shunkichi
    Watanabe, Yoichi
    Sugimoto, Keisuke
    Shibayama, Takuo
    Yonei, Toshiro
    Ueoka, Hiroshi
    Takemoto, Mitsuhiro
    Kanazawa, Susumu
    Takata, Ichiro
    Nogami, Naoyuki
    Hotta, Katsuyuki
    Hiraki, Akio
    Tabata, Masahiro
    Matsuo, Keitaro
    Tanimoto, Mitsune
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) : 3299 - 3306
  • [10] Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer
    Sekine, Ikuo
    Nokihara, Hiroshi
    Sumi, Minako
    Saijo, Nagahiro
    Nishiwaki, Yutaka
    Ishikura, Satoshi
    Mori, Kiyoshi
    Tsukiyama, Iwao
    Tamura, Tomohide
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (08) : 810 - 815